预约演示
更新于：2026-01-15
Carboxyamidotriazole
羧胺三唑
更新于：2026-01-15
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H12Cl3N5O2 |
InChIKeyWNRZHQBJSXRYJK-UHFFFAOYSA-N |
CAS号99519-84-3 |
关联
10
项与 羧胺三唑 相关的临床试验ITMCTR2025001431
A Clinical Intervention Study Investigating Cai's Therapy in the Management of Overweight and Obesity
JPRN-UMIN000052851
Study on the usefulness of Carbonic Anhydrase I (CA I) protein as an enteritis biomarker in faeces and colonic tissue from patients with ulcerative colitis and its effect on the intestinal microbiota. - UC-CA1 Study
CTR20160395
随机、双盲、多中心羧胺三唑胶丸联合NP对照安慰剂联合NP治疗初治的Ⅳ期非小细胞肺癌患者的Ⅲ期临床研究
100 项与 羧胺三唑 相关的临床结果
登录后查看更多信息
100 项与 羧胺三唑 相关的转化医学
登录后查看更多信息
100 项与 羧胺三唑 相关的专利（医药）
登录后查看更多信息
275
项与 羧胺三唑 相关的文献（医药）2025-12-01JOURNAL OF NEURO-OPHTHALMOLOGY
Assessing the Risk of Kidney Stone Development in Patients With Idiopathic Intracranial Hypertension Treated With Carbonic Anhydrase Inhibitors
Article
作者: Al Deyabat, Osama ; Muayad, Jawad ; Lee, Andrew G ; Alryalat, Saif Aldeen ; Loya, Asad
Background::
The prevalence of idiopathic intracranial hypertension (IIH) is rising with the global obesity epidemic. Carbonic anhydrase inhibitors (CAIs), such as acetazolamide, have been shown to be effective in IIH but can also lead to kidney stone formation. This study evaluates the risk of kidney stone development in patients with IIH treated with CAIs.
Methods::
A retrospective cohort study using the TriNetX database was performed to compare patients with IIH treated with CAIs vs. untreated controls. Propensity score matching (PSM) balanced demographic and clinical variables. The primary outcome was kidney stone incidence for 3 time intervals: 1 year, 1–2 years, and 2–3 years, identified using International Classification of Diseases-10 codes. Risk ratios (RRs) with 95% confidence intervals (CIs) assessed the association between CAI treatment and kidney stone formation.
Results::
The study evaluated 23,182 patients with IIH treated with CAIs compared with 50,080 untreated controls. After applying PSM, each group was balanced to include 22,464 patients. The treated group had a significantly higher risk of developing kidney stones than the control group, with an RR of 1.49 (95% CI: 1.22–1.84) at 1 year, 2.24 (95% CI: 1.61–3.12) at 1–2 years, and 1.51 (95% CI: 1.05–2.18) at 2–3 years. Sensitivity analysis of patients treated with at least 500 mg of acetazolamide shared this elevated trend, and the risk remained persistently high at 2–3 years (RR: 2.18, 95% CI: 1.13–4.20). Subgroup analysis revealed higher risks in males, while Black or African American patients had a lower risk.
Conclusions::
Carbonic anhydrase inhibitor use in patients with IIH may increase kidney stone risk, particularly in certain populations. Further research is needed to understand the mechanisms behind this risk and to optimize treatment strategies.
2025-10-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Antimicrobial use in pediatric patients: a subgroup analysis of the 2020 point prevalence survey in Aichi, Japan
Article
作者: Mutoh, Yoshikazu ; Nagaoka, Masatoshi ; Akita, Kenji ; Hasegawa, Chihiro ; Tomita, Yuka ; Ito, Kenta ; Ishihara, Masamitsu ; Hamada, Hiroshi ; Okudaira, Masami ; Kato, Hiroki ; Oka, Keisuke ; Ito, Yuji ; Tsuji, Takeshi ; Shimizu, Junichi ; Nozaki, Yasuhiro ; Yokota, Manabu ; Koizumi, Yusuke ; Kojima, Yumi ; Yagi, Tetsuya ; Iwata, Susumu ; Watariguchi, Toshitaka ; Kawasaki, Shohei ; Watamoto, Koichi ; Morioka, Hiroshi
BACKGROUND:
Establishing the precise epidemiology of antimicrobial use (AMU) is essential to promote antimicrobial stewardship. However, data on AMU for pediatric inpatients in Japanese hospitals are lacking. In this study, we performed a subgroup analysis focusing on pediatric patients from a point prevalence survey.
METHODS:
A multicenter point prevalence survey was conducted in Aichi Prefecture in 2020. This subgroup analysis included pediatric patients (≦18 years old) and assessed AMU and their indications: community-acquired infections (CAIs), healthcare-associated infections (HAIs), medical prophylaxis (MP), and surgical prophylaxis (SP). Details of infections and interventions by the antimicrobial stewardship teams (AST) were also surveyed.
RESULTS:
Of the 736 patients from 23 hospitals included in this study, 241 patients (32.7 %, 95 % confidence interval [95 % CI]: 29.4-36.3) received a total of 399 antimicrobials. The prevalence of HAI was 6.0 % (95 % CI: 4.4-7.9). The number of antimicrobials administered per 100 patients ranged from 24.1 in small hospitals to 109.6 in university hospitals. CAI treatment was the most common indication in community hospitals, SP in specific centers, and MP in university hospitals. The most commonly prescribed antimicrobials were cefotaxime for CAI, meropenem for HAI, trimethoprim-sulfamethoxazole for MP, and cefazolin for SP. A total of 78 CAIs and 46 HAIs were identified, with AST intervention rates of 2.5 % and 34.8 %, respectively.
CONCLUSION:
This subgroup analysis provides the first demographic data on AMU among pediatric inpatients at Japanese hospitals. The distinct distribution of AMU suggests that different approaches are necessary to promote antimicrobial stewardship in hospital settings.
2025-10-01PROTEIN EXPRESSION AND PURIFICATION
Column-free purification of functional HIV-1 capsid protein and its application in assembly and inhibitor assays
Article
作者: Xu, Xiao-Shuang ; Chang, Shan ; Li, Yimin ; Zhang, Da-Wei
The HIV-1 capsid protein (CA) is essential for viral replication and serves as a validated antiviral drug target. Traditional purification of CA relies on multi-step chromatographic protocols, which are time-consuming and labor-intensive. In this study, we established a rapid, column-free purification strategy using a cleavable self-aggregating tag (cSAT) to produce functional wild-type CA protein from E. coli with >95 % purity within a single day. The workflow is compatible with high-throughput formats and scalable from microplates to fermenters, offering significant advantages over conventional purification methods. The purified CA retained full biological activity, as demonstrated by its ability to assemble into higher-order structures in a salt- and protein concentration-dependent manner in vitro. We further evaluated the effects of two well-characterized capsid modulators: CAI, a peptide inhibitor, and lenacapavir (LEN), a clinically approved capsid-targeting drug. Turbidity-based assembly assays confirmed that CAI inhibited and LEN enhanced CA assembly in a dose-dependent manner. When co-administered, CAI and LEN exhibited mutually antagonistic effects. Preincubation with CAI abolished LEN-mediated enhancement, indicating a potential conformational lock imposed by CAI. These findings demonstrate that the column-free strategy enables efficient production of functionally active CA protein suitable for downstream biochemical and inhibitor screening assays. The approach provides a practical tool for accelerating HIV-1 capsid research and antiviral discovery.
100 项与 羧胺三唑 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非小细胞肺癌 | 申请上市 | 中国 | 2021-07-08 | |
| 转移性非小细胞肺癌 | 临床3期 | 美国 | 1999-04-01 | |
| 非小细胞肺癌IIIA期 | 临床3期 | 美国 | 1999-04-01 | |
| 非小细胞肺癌IIIB期 | 临床3期 | 美国 | 1999-04-01 | |
| 转移性肾细胞癌 | 临床2期 | 美国 | 2000-10-01 | |
| 多形性胶质母细胞瘤 | 临床2期 | 美国 | 2000-03-01 | |
| 神经胶质肉瘤 | 临床2期 | 美国 | 2000-03-01 | |
| 输卵管癌 | 临床2期 | 美国 | 1998-04-01 | |
| 铂类耐药性原发性腹膜癌 | 临床2期 | 美国 | 1998-04-01 | |
| 复发性原发性腹膜癌 | 临床2期 | 美国 | 1998-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 55 | (CAI With RT - Arm 1) | 夢獵範廠鹽鬱衊襯襯積(齋鹽艱獵艱醖襯膚築網) = 鑰餘鏇糧構鑰範網網製 壓鹽顧襯艱蓋製壓獵糧 (糧築蓋憲觸鑰壓鏇鏇衊, 遞餘網鏇鏇憲鹽夢選蓋 ~ 餘壓艱夢積範鏇餘範蓋) 更多 | - | 2015-05-08 | ||
(CAI With RT + Enzyme Inducing Anticonvulsants) | 築獵壓遞鹽鹹鑰衊網鹽(網繭窪獵蓋廠鑰糧範製) = 艱築遞憲蓋齋獵襯餘築 廠顧觸蓋窪鏇遞鏇艱醖 (鏇遞餘鬱壓選齋選範製, 1.22) | ||||||
临床3期 | 186 | (Carboxyamidotriazole) | 壓網糧餘鹹構製齋簾願(範窪夢鏇築築鑰鹹觸構) = 醖鬱衊窪製膚積網鹽窪 襯壓蓋繭簾壓築獵築衊 (選積鑰獵鏇簾鹹繭範鬱, 範餘淵艱範鏇鹹顧膚醖 ~ 糧網鑰鏇獵製窪鹹鑰餘) 更多 | - | 2010-12-22 | ||
placebo (Placebo) | 壓網糧餘鹹構製齋簾願(範窪夢鏇築築鑰鹹觸構) = 積積鬱鬱遞繭齋廠範襯 襯壓蓋繭簾壓築獵築衊 (選積鑰獵鏇簾鹹繭範鬱, 襯範糧膚淵蓋餘餘積夢 ~ 鑰構糧窪膚選製衊鏇襯) 更多 | ||||||
临床3期 | 晚期非小细胞肺癌 维持 | 186 | 憲蓋糧鏇衊範顧鏇艱願(憲範積願遞淵鹽齋繭鹽) = 顧齋築膚繭積積廠蓋築 廠壓襯衊範獵膚觸網鹹 (繭鹹齋壓鏇鹽積夢遞選 ) 更多 | 不佳 | 2005-06-01 | ||
Placebo | 憲蓋糧鏇衊範顧鏇艱願(憲範積願遞淵鹽齋繭鹽) = 鹽蓋網餘選襯築遞鬱餘 廠壓襯衊範獵膚觸網鹹 (繭鹹齋壓鏇鹽積夢遞選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用